Elpiscience

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies #immunooncology #ChinaBiotech

[John Craighead @john_craighead]

Excited to share @US_FDA has cleared @Elpiscience's ES014 IND to initiate Ph1 study. ES014 is a novel anti-#CD39-#TGFbeta bispecific antibody targeting two major #tumormicroenvironment immunosuppressive mechanisms #adenosine #immunooncology #ChinaBiotech https://t.co/1tZzZWrlaA

[John Craighead @john_craighead]

Congratulations @Elpiscience partner $CMPX on positive interim ES104 Ph2 data in combo w/ paclitaxel in #BiliaryTractCancer. Excited to progress this potential new option for #ColorectalCancer, #CholangioCarcinoma and #GastricCancer patients in China https://t.co/quHJUG4aMO

[John Craighead @john_craighead]

We are excited to initiate this @Elpiscience DLL4-VEGF bispecific antibody Ph1/2 study. In Ph1 ES104 showed encouraging single-agent activity in advanced #ColorectalCancer and #GastricCancer patients resistant to anti-VEGF #clinicaltrials #ChinaBiotech https://t.co/fEgQYVVy0a

[John Craighead @john_craighead]

Great news for cancer patients worldwide with Elpiscience #CD39 mAb IND clearance in China, which follows the recent Phase I clinical study initiation in the US! #oncology #adenosine #ChinaBiotech #immunooncology #clinicaltrials
https://t.co/CEpzFyfQ35

[John Craighead @john_craighead]

Exciting clinical progress for patients! #Elpiscience #immunotherapy #oncology
https://t.co/UXuRKERGXU

[John Craighead @john_craighead]

I'm excited to join Elpiscience Biopharmaceuticals as CFO to support the company’s robust pipeline of innovative cancer immunotherapies and mission to transform the lives of patients suffering from cancer https://t.co/ZBC6xzRspT